MedTrace Logo

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

NCT06929624 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

DRUG

SHR-A1912 Injection

SHR-A1912 injection.

DRUG

Rituximab Injection

Rituximab injection.

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine hydrochloride for injection.

DRUG

Oxaliplatin Injection

Oxaliplatin injection.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-24
Primary Completion
2027-03-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929624 on ClinicalTrials.gov